MiNK Therapeutics
INKT
42 hedge funds and large institutions have $3.1M invested in MiNK Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 2 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 2
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
250% more funds holding
Funds holding: 12 → 42 (+30)
169% more capital invested
Capital invested by funds: $1.15M → $3.1M (+$1.95M)
2.5% more ownership
Funds ownership: 1.79% → 4.29% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$651K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$385K |
| 3 |
Renaissance Technologies
New York
|
+$271K |
| 4 |
BlackRock
New York
|
+$143K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LF
Longbow Finance
Lutry,
Switzerland
|
-$316K |
| 2 |
AG
Artal Group
Luxembourg
|
-$123K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$61.4K |
INKT Hedge Fund Activity: Q2 2023 in Review
42 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2023, worth a combined $3.1M — up 169% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new INKT positions and 2 closed out — a net gain of 30 holders — while 9 added to existing stakes and 1 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $651K. The largest seller was Longbow Finance, exiting entirely with an estimated $316K sold.
- 42 institutional investors held MiNK Therapeutics (INKT) as of Q2 2023, up from 12 in Q1 2023.
- Funds reported $3.1M of MiNK Therapeutics stock for Q2 2023, up 169% quarter-over-quarter.
- 32 funds opened new MiNK Therapeutics positions in Q2 2023 and 2 closed out, a net change of +30 holders.
- The largest MiNK Therapeutics buyer in Q2 2023 was Deep Track Capital, an estimated $651K added.
- The largest MiNK Therapeutics seller in Q2 2023 was Longbow Finance, an estimated $316K sold.
Based on aggregated 13F filings for Q2 2023.